Try these holistic remedies to get relief for irritated skin.
US biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream in adults and adolescents aged 12 or above, sending its shares ticking up.
By Stephen Beech A new way of treating common inflammatory skin conditions such as eczema is on the horizon, according to a ...
Researchers say a compound called SYM2081 inhibits inflammation-driving mast cells in mice and human skin samples paving the ...
A daily cream containing a GluK2-activating compound could therefore be a promising way to prevent several inflammatory skin conditions.